• Isoliensinine Modulates TRPV1-AMPK to Attenuate MAFLD Fibros

  2026-07-22

  This study elucidates how isoliensinine from Plumula Nelumbinis ameliorates hepatic fibrosis in metabolic associated fatty liver disease (MAFLD) by restoring lipid droplet metabolism through TRPV1-AMPK activation. These findings highlight a mechanistic link between calcium homeostasis, lipid storage, and anti-fibrotic effects, suggesting potential translational routes for metabolic disease research.

• CB-5083: Applied p97 Inhibitor Workflows in Cancer Models

  2026-07-22

  CB-5083 enables precise disruption of protein homeostasis and potent induction of apoptosis in cancer research, thanks to its selectivity and in vivo efficacy. This guide bridges the latest mechanistic discoveries on p97 and stress granule regulation with optimized experimental workflows and troubleshooting strategies.

• Cyanine 3-dCTP (SKU B8159): Reliable Fluorescent DNA Labelin

  2026-07-21

  This article provides an evidence-driven guide for biomedical researchers and lab technicians tackling challenges in direct enzymatic DNA and cDNA labeling. Using 'Cyanine 3-dCTP' (SKU B8159), we examine reproducibility, sensitivity, protocol optimization, and vendor reliability—grounded in data, peer-reviewed literature, and real-world laboratory scenarios.

• Applied Insights: Puromycin Aminonucleoside in Podocyte Inju

  2026-07-21

  Puromycin aminonucleoside is the gold-standard reagent for inducing nephrotic syndrome and podocyte injury in experimental models, enabling mechanistically faithful studies of glomerular pathology. This guide translates bench protocols, troubleshooting strategies, and new mechanistic findings into actionable workflows, maximizing the impact of APExBIO’s high-purity compound in renal research.

• Super-Enhancer Hijacking of LINC01977 in Early Lung Adenocar

  2026-07-20

  Zhang et al. (2022) uncovered a mechanism in early-stage lung adenocarcinoma where a super-enhancer hijacks the lncRNA LINC01977, amplifying tumor aggressiveness via the TGF-β/SMAD3 axis. These findings highlight new epigenetic vulnerabilities and suggest that targeting transcriptional coactivators may present valuable research opportunities in cancer biology.

• Müller Cell PEDF and Angiopoietin Signaling in Retinal Neuro

  2026-07-20

  This study establishes that Müller cell-derived pigment epithelium-derived factor (PEDF) is a critical modulator of retinal neuron survival via angiopoietin-dependent Tie-2 signaling. The findings clarify how Ang-1 and Ang-2 differentially regulate neuroprotective and angiogenic pathways, revealing new molecular targets for retinal neuroprotection and anti-angiogenic intervention.

• Refining In Vitro Drug Response Metrics for Cancer Research

  2026-07-19

  Schwartz’s dissertation introduces a dual-metric framework that distinguishes between proliferative arrest and cell death when evaluating anti-cancer drugs in vitro. This nuanced approach challenges the field’s reliance on single-parameter assays, offering researchers improved tools for dissecting drug effects and guiding rational therapeutic development.

• Erlotinib (NSC 718781): Applied EGFR Inhibition in Cancer Mo

  2026-07-18

  Erlotinib (NSC 718781) enables precise dissection of EGFR-driven oncogenic signaling and resistance mechanisms in translational cancer research. This guide details optimized workflows, troubleshooting strategies, and actionable insights to maximize reproducibility and performance in EGFR pathway inhibition studies.

• Dimethyloxalylglycine (DMOG): Technical Use & Protocol Guide

  2026-07-17

  Dimethyloxalylglycine (DMOG) is a cell-permeable PHD inhibitor for stabilizing hypoxia-inducible factors in controlled research settings. It is suited for in vitro and in vivo modeling of hypoxia-related signaling and inflammation, but is not intended for diagnostic or clinical use. Researchers must observe solubility, storage, and workflow limits for reproducible results.

• Patient-Derived Gastric Cancer Assembloids Advance Tumor Mod

  2026-07-17

  This study introduces a patient-specific gastric cancer assembloid model that integrates matched tumor organoids with stromal cell subpopulations, effectively recapitulating the cellular and molecular complexity of primary tumors. The approach enables improved drug response prediction and supports mechanistic studies of tumor–stroma interactions, with significant implications for personalized cancer therapy.

• Intravesical p21 mRNA-LNP: Localized Tumor Suppressor Therap

  2026-07-16

  Zeng et al. (2026) introduce a localized, non-viral approach to restore tumor suppressor function in bladder cancer by intravesical delivery of p21 mRNA-loaded lipid nanoparticles. Their findings demonstrate robust tumor inhibition and preservation of bladder architecture, advancing the translational promise of mRNA therapeutics for targeted, site-specific cancer treatment.

• AP1903: FKBP-Binding Ligand for Precision Cell Ablation Work

  2026-07-16

  AP1903 empowers researchers to achieve highly controlled protein activation and conditional cell ablation in engineered systems. Its nanomolar potency and compatibility with multiplexed assay formats make it a cornerstone for advanced apoptosis pathway research and functional genomics.

• Applied Workflows for Amikacin (BAY416651) in Resistance Res

  2026-07-15

  Amikacin (BAY416651) stands out as a robust bacterial protein synthesis inhibitor, uniquely resistant to most aminoglycoside-modifying enzymes. This guide delivers actionable protocols, troubleshooting insights, and strategic comparisons that help researchers maximize data quality in antibiotic resistance studies—especially with multidrug-resistant Enterobacter cloacae and Klebsiella pneumoniae.

• Sulfo-NHS-Biotin: Precision Tools for CNS Vascular Biology

  2026-07-15

  Discover how Sulfo-NHS-Biotin, a leading protein labeling reagent, advances cell surface biotinylation for investigating the molecular mechanisms of CNS angiogenesis and blood–brain barrier integrity. This article uniquely integrates biochemical technique with recent neurovascular research.

• DDI2-NFE2L1-Proteasome Axis Protects Cells from Ferroptosis

  2026-07-14

  This study uncovers how DDI2-dependent activation of NFE2L1 restores proteasome function to protect cells from ferroptosis, an iron-dependent, non-apoptotic cell death. The research highlights a feedback mechanism within the ubiquitin-proteasome system and demonstrates the sensitization of cells to ferroptosis by inhibiting DDI2, including with Nelfinavir Mesylate, opening avenues for therapeutic modulation.

14723 records 1/982 page Next 12345 下5页 Last page